Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a collaboration with an unnamed Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients.
The company said the initial program will focus on the feasibility of developing a biobased pathway and advancing it toward commercialisation.
The development phase of this funded collaboration is expected to last approximately two months, it added.
"We are honored to have been selected by such a forward-thinking biopharmaceutical company to jointly explore innovative pathways toward the development of sustainably sourced intermediates and APIs," Dr. Chris Savile, Willow's president and CEO, said in a statement.
"If successful, we believe that by leveraging biobased routes, these ingredients essential for human health can be made more broadly available while providing a solution for overseas supply chain issues that can increase cost and potentially create shortages."
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets.